Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 3/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.37 |
| ▸ | CSF1R | P07333 | 2/20 | 0.36 |
| ▸ | DHFR | P00374 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2725563 | 0.83 | PDPK1 (0.44) | PDPK1TAAR1DHFRKDRADORA2A | |
| SCHEMBL2725988 | 0.75 | PDPK1 (0.42) | PDPK1RXRARXRBRXRGDHFR | |
| SCHEMBL15100699 | 0.74 | RECQL (0.47) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL2724359 | 0.71 | SMN1; SMN2 (0.48) | PDPK1RXRARXRBRXRGDHFR | |
| SCHEMBL1317516 | 0.71 | SMN1; SMN2 (0.61) | RXRARXRBRXRGDHFRSMN1; SMN2 | |
| SCHEMBL25453063 | 0.71 | EGFR (0.46) | PDPK1RXRARXRBRXRGHTR3E | |
| SCHEMBL30502771 | 0.71 | EGFR (0.46) | PDPK1RXRARXRBRXRGHTR3E | |
| SCHEMBL14214689 | 0.70 | EGFR (0.48) | RXRARXRBRXRGHTR3EHTR3B | |
| SCHEMBL2723983 | 0.70 | SMN1; SMN2 (0.34) | PDPK1EGFRDHFRSMN1; SMN2KDR | |
| SCHEMBL2726547 | 0.70 | PDPK1 (0.42) | PDPK1DHFRSMN1; SMN2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238651-B2 | 1-H-pyrrolo[2,3-b]pyridine derivatives | MERCK PATENT GMBH (DE) | 2016-01-19 | — | — | US | disclosed |
| CN-103180320-B | 1H-pyrrolo [2,3-b ] pyridine derivatives | MERCK PATENT GMBH (DE) | 2015-10-07 | — | — | CN | disclosed |
| US-20140371215-A1 | 1-H-Pyrrolo[2,3-b]Pyridine Derivatives | MERCK PATENT GMBH (DE) | 2014-12-18 | — | — | US | disclosed |
| US-8895575-B2 | 1 H-pyrrolo[2,3-b]pyridine derivatives | MERCK PATENT GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| EP-2635574-B1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-09-10 | — | — | EP | disclosed |
| US-20140100221-A1 | 1H-Pyrrolo[2,3-b]Pyridine Derivatives | MERCK PATENT GMBH (DE) | 2014-04-10 | — | — | US | disclosed |
| US-8664236-B2 | 1H-pyrrolo[2,3 b]-pyridine derivatives | MERCK PATENT GMBH (DE) | 2014-03-04 | — | — | US | disclosed |
| EP-2635574-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-09-11 | — | — | EP | disclosed |
| US-20130231519-A1 | 1H-Pyrrolo[2,3 b]pyridine derivatives | MERCK PATENT GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| CN-103180320-A | 1H-pyrrolo [2,3-b ] pyridine derivatives | MERCK PATENT GMBH | 2013-06-26 | — | — | CN | disclosed |
| WO-2012059172-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371215-A1 | 1-H-Pyrrolo[2,3-b]Pyridine Derivatives | MKI67, CDK4, CCNH | PDPK1 71/4885RXRA 3704/4885RXRB 2757/4885 |
| US-20130231519-A1 | 1H-Pyrrolo[2,3 b]pyridine derivatives | MKI67, CDK4, TP53 | PDPK1 67/4885RXRA 3505/4885RXRB 2480/4885 |
| US-20140100221-A1 | 1H-Pyrrolo[2,3-b]Pyridine Derivatives | MKI67, CDK4, TP53 | PDPK1 48/4885RXRA 3513/4885RXRB 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.